Jansen-Olesen Inger, Baun Michael, Amrutkar Dipak V, Ramachandran Roshni, Christophersen Daniel V, Olesen Jes
Danish Headache Center and Department of Neurology, Glostrup Hospital, Faculty of Health Sciences, University of Copenhagen, Glostrup, Denmark.
Danish Headache Center and Department of Neurology, Glostrup Hospital, Faculty of Health Sciences, University of Copenhagen, Glostrup, Denmark.
Neuropeptides. 2014 Apr;48(2):53-64. doi: 10.1016/j.npep.2014.01.004. Epub 2014 Jan 25.
To investigate if PACAP and VIP have an effect on CGRP release or NOS activity in the trigeminal ganglion and trigeminal nucleus caudalis and if there can be a difference in effect between PACAP and VIP on these two systems. Furthermore, we investigate if PACAP co-localize with CGRP and/or nNOS in the two tissues.
The structurally related neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide-38 (PACAP-38) partially share receptors and are both potent vasodilators. However, PACAP-38 but not VIP is an efficient inducer of migraine attacks in migraineurs. Calcitonin gene-related peptide (CGRP) and nitric oxide (NO) are two signaling molecules known to be involved in migraine.
Rat tissue was used for all experiments. Release of CGRP induced by VIP and PACAP in dura mater, trigeminal ganglion (TG) and trigeminal nucleus caudalis (TNC) was quantified by EIA. Regulation of NOS-enzymes caused by VIP and PACAP was investigated in dura mater, TG and TNC by measuring the conversion of L-[3H]arginine to L-[3H]citrulline. Co-expression of PACAP, neuronal nitric oxide synthase (nNOS) and CGRP was explored by immunohistochemistry in TG and TNC. mRNA expression studies of VPAC1, VPAC2 and PAC1-receptors were performed by qRT-PCR.
PACAP-38 administered in increasing concentrations caused a concentration-dependent CGRP-release in the TNC, but not in TG. VIP was without effect in both tissues examined. The PAC1 receptor agonist maxadilan had no effect on CGRP release and the PAC1 antagonist M65 did not inhibit PACAP-38 induced CGRP release. PACAP-38 or VIP did not affect NOS activity in homogenates of TG and TNC. Quantitative PCR demonstrated the presence of VPAC1, VPAC2 and PAC1 receptors in TG and TNC. Immunohistochemistry of PACAP and CGRP showed co-expression in TG and TNC. PACAP and nNOS were co-localized in TG, but not in TNC. PACAP was found to co-localize with glutamine synthetase in TG satellite glial cells.
PACAP-38 cause release of CGRP from TNC but not from TG. We suggest that the release is not caused via activation of PAC1, VPAC1 or VPAC2 receptors. PACAP has no effect on NOS activity in TG or TNC. In TG PACAP was found in neuronal cells and in satellite glial cells. It co-localized with CGRP and nNOS in the neuronal cells. In TNC PACAP was co-localized with CGRP but not with nNOS.
研究垂体腺苷酸环化酶激活肽(PACAP)和血管活性肠肽(VIP)是否对三叉神经节和三叉神经尾侧核中降钙素基因相关肽(CGRP)的释放或一氧化氮合酶(NOS)活性有影响,以及PACAP和VIP对这两个系统的作用是否存在差异。此外,我们还研究PACAP在这两种组织中是否与CGRP和/或神经元型NOS(nNOS)共定位。
结构相关的神经肽血管活性肠肽(VIP)和垂体腺苷酸环化酶激活肽-38(PACAP-38)部分共享受体,且均为强效血管舒张剂。然而,PACAP-38而非VIP是偏头痛患者偏头痛发作的有效诱导剂。降钙素基因相关肽(CGRP)和一氧化氮(NO)是已知参与偏头痛的两种信号分子。
所有实验均使用大鼠组织。通过酶免疫分析(EIA)定量检测VIP和PACAP诱导硬脑膜、三叉神经节(TG)和三叉神经尾侧核(TNC)中CGRP的释放。通过测量L-[3H]精氨酸向L-[3H]瓜氨酸的转化,研究VIP和PACAP对硬脑膜、TG和TNC中NOS酶的调节作用。通过免疫组织化学在TG和TNC中探索PACAP、神经元型一氧化氮合酶(nNOS)和CGRP的共表达。通过实时定量聚合酶链反应(qRT-PCR)进行VPAC1、VPAC2和PAC1受体的mRNA表达研究。
递增浓度给予PACAP-38可导致TNC中CGRP释放呈浓度依赖性,但在TG中无此现象。VIP在所检测的两种组织中均无作用。PAC1受体激动剂马西替坦对CGRP释放无影响,PAC1拮抗剂M65也不抑制PACAP-38诱导的CGRP释放。PACAP-38或VIP对TG和TNC匀浆中的NOS活性无影响。定量PCR证实TG和TNC中存在VPAC1、VPAC2和PAC1受体。PACAP和CGRP的免疫组织化学显示在TG和TNC中共表达。PACAP和nNOS在TG中共定位,但在TNC中不共定位。发现PACAP在TG卫星神经胶质细胞中与谷氨酰胺合成酶共定位。
PACAP-38可导致CGRP从TNC释放,但不能从TG释放。我们认为这种释放不是通过激活PAC1、VPAC1或VPAC2受体引起的。PACAP对TG或TNC中的NOS活性无影响。在TG中,PACAP存在于神经元细胞和卫星神经胶质细胞中。它在神经元细胞中与CGRP和nNOS共定位。在TNC中,PACAP与CGRP共定位,但与nNOS不共定位。